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Sarcomas are rare tumours. Early diagnosis is challenging, but important for local control
and potentially survival and quality of life(QoL). We investigated (1)the route to diagnosis
(RtD) experienced by sarcoma patients, including factors contributing to the length of the
RtD from patients’ perspective; (2)the impact of the RtD on QoL and care satisfaction; and
(3)differences in aims 1–2 between English and Dutch patients.
Methods
Fifteen sarcoma patients from The Royal Marsden Hospital, United Kingdom, and Radboud
University Medical Centre, The Netherlands, were interviewed, exploring RtD experiences.
Interviews were analysed according to qualitative content analysis.
Results
The main themes were: patient interval, diagnostic interval, reflection on the RtD and recom-
mendations for improvement. Patient interval was long if symptoms were attributed as
benign, did not interfere with daily life or were expected to cease. An incorrect working diag-
nosis, ineffective process of additional investigations, long referral times and lack of a lead
clinician lengthened the diagnostic interval. Long waiting times, false reassurance and inad-
equate information provision led to dissatisfaction and a high emotional burden. Factors for
improvement included increasing awareness of patients and healthcare providers, empow-
ering patients, and having a lead clinician.
Conclusion
The RtD of sarcoma patients is complex. Increasing awareness of patients and healthcare
providers may contribute to shorten the RtD.
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Introduction
Sarcomas are mesenchymal tumours which comprise more than 70 histological subtypes. They
are heterogeneous in terms of age of onset, presentation, anatomic location, speed of progression
and clinical outcome. Approximately 85% of sarcomas originate in soft tissue, the remainder in
bone. Sarcomas have an estimated incidence averaging 4–5 per 100,000 per year in Europe [1]
and are a so-called rare cancer. Patients with rare cancers have a higher mortality rate than those
with common cancers because of delays in accurate diagnosis, suboptimal or inadequate treat-
ment, fewer opportunities to participate in clinical trials and less availability of novel agents [2].
Early and adequate diagnosis of sarcoma is challenging due to the heterogeneity in presenta-
tion and histology, but is important for local control, and potentially (health-related) quality of
life ((HR)QoL) and survival, as seen in other cancer diagnoses [3–8]. Different histological sar-
coma subtypes vary in biological behaviour; some aggressive sarcomas cause severe symptoms at
an early stage, leading to an early presentation and potentially faster diagnosis, but with a worse
outcome than sarcomas that grow slow, causing symptoms with a long total interval. The total
interval is the time between first symptoms and (preferably histological) diagnosis (Fig 1) [9].
Apart from cancer characteristics, patient and healthcare factors can be of influence on the
length of the total interval [9, 10]. Until now, contradictory results have been found for the
influence of patient characteristics [11]; data on comparison of healthcare systems is scarce for
sarcomas. The healthcare system of The Netherlands(NL) and United Kingdom(UK) are com-
parable but differ regarding sarcoma referral pathways.
Patients in both countries have access to health services via a publicly funded healthcare sys-
tem [12] and generally the general practitioner (GP) is the first healthcare provider(HCP) to
Fig 1. Definitions of the route to diagnosis for sarcoma patients. This fig was adapted from Olesen et al and Walter et al [9, 13, 14].
>Patient interval: from the date the patient first noticed a sarcoma related symptom until the first presentation to a doctor with this
symptom; -Appraisal: from noticing a sarcoma related symptom to deciding to seek the help of a healthcare provider (HCP); -Help-seeking:
from making the decision to consult a HCP until the actual appointment;>Diagnostic interval: from first presentation to a doctor until
diagnosis; -Primary care interval: from first presentation to a general practitioner (GP) until first referral to secondary (if applicable) or
tertiary care, in this study the sarcoma centre (in which referral is the time point at which there is a transfer of responsibility from one HCP
to another); -Secondary care interval: from referral to secondary care specialist until referral to tertiary care specialist; -Tertiary care
interval: from referral to tertiary care specialist (sarcoma centre) until date of histological diagnosis;>Total interval: from first symptom
until histological diagnosis.
https://doi.org/10.1371/journal.pone.0243439.g001
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The Netherlands; UK, United Kingdom; GP, general
practitioner; HCP, healthcare provider.
be consulted, who refers to secondary or tertiary centres if appropriate. In the UK a minority
of patients (11%) is privately insured giving them access to private hospitals via self-referrals,
in NL patients may, if they can afford it, use certain diagnostic services provided in private
clinics. Sarcoma care has been centralized in the UK, and although bone sarcoma centres exist
in NL, care for patients with soft tissue sarcomas has not formally been centralized.
The aim of this study is to investigate (1)the route to diagnosis(RtD) experienced by sar-
coma patients, including factors contributing to the length of the total interval from the per-
spective of a patient; (2)the impact of the RtD length on QoL and care satisfaction; and (3)
differences in aims 1–2 between English and Dutch patients.
Methods
Conceptual framework
To study the RtD, a framework for research with clear definitions is needed. In this study we
combined the widely used models of Olesen et al and Walter et al, as shown in Fig 1 [9, 13, 14].
The combined model identifies a patient interval, which can be divided between the process of
appraisal and help-seeking, and a diagnostic interval, which can be divided into a primary, sec-
ondary, and tertiary care interval, the latter was added to fit the sarcoma referral pathway. The
treatment interval was left out, as it is out of the scope of this study. The events marking the
beginning and end of each interval can be found in Fig 1. The length of each interval can be
influenced by patient, system and tumour factors, which will eventually influence clinical and
patient-reported outcomes, represented by the outcomes column to the right. This theoretical
framework will be used to describe patients’ experience of the sarcoma RtD.
Study design and patient recruitment
We conducted semi-structured interviews between March and November 2017. Patients were
eligible if they were (1)�18 years; (2)diagnosed within the past 4 months in Radboud Univer-
sity Medical Centre (Radboudumc), NL, or the Royal Marsden NHS Foundation Trust, UK,
with histological proven sarcoma and (3)could communicate in Dutch or English, respectively.
Patients with significant cognitive impairment or mental health problems, as determined by
their HCP, were excluded.
At both sites, eligible patients were identified by their HCP or a member of the research
team (VS) and supplied with an information letter. VS then contacted the patients to answer
remaining questions and, if agreeing to participate, to set a time for the interview. All partici-
pants provided written informed consent before the interviews. Participants completed demo-
graphic and clinical questions prior to the interview. RtD, QoL, and care satisfaction were
subjects within the interview, and not subject of the questionnaire.
In the UK the study was deemed exempt from full review and approval by a research ethics
committee (Committee for Clinical Research, Royal Marsden NHS Foundation Trust), but
was approved by the service evaluation committee of the Royal Marsden NHS Foundation
Trust (SE669). In NL the study was approved by the medical ethical committee of the Radbou-
dumc (2017–3229).
Data collection, analysis and reporting
Patients completed a short questionnaire on sociodemographic data and dates of referral. Date
of referral to the sarcoma centre and the date of histological diagnosis was confirmed from
medical records.
PLOS ONE The route to diagnosis of sarcoma patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0243439 December 7, 2020 3 / 14
Semi-structured interviews were conducted by one member of the research team at both
sites (VS), the interview schedule is provided in S1 Appendix. VS had no clinical relationship
with the participants or the treating physician. The interviews were conducted at the hospital.
Topics and questions were based on clinical experience and literature review [11, 15–17],
whilst emerging questions from interviews were discussed in the following interviews. The
interviews were recorded and transcribed verbatim and anonymously. Data analysis was con-
ducted by two coders (VS and OH) using ATLAS.ti 8.0. Data was analysed according to quali-
tative content analyses and were ordered into relevant code terms, and then categorised into
themes by two researchers (VS and OH). Data answering the first research question was orga-
nized according to our conceptual framework (directed approach) [18]. The second and third
research question were answered by conventional content analyses, in which coding categories
are derived directly from the data [18]. After analysing the data independently, the coders dis-
cussed and redefined until they reached consensus. Saturation was reached when no new
themes were identified. The consolidated criteria for reporting qualitative research (COREQ)
were used. S2 Appendix provides an overview of translated quotes.
Results
Participants
Seven Dutch and eight English patients with a total interval varying between 10–145 weeks
participated. All invited patients gave informed consent and participated in the study. Both
patient and diagnostic interval contributed to a prolonged total interval: though the median
patient interval was 4 weeks, it ranged from 0–119 weeks; the median diagnostic interval was
18 weeks with a range of 3–140 weeks. More details on these intervals and socio-demographic
and clinical characteristics of the patients are presented in Table 1. The study participants
reflect the heterogeneity of the sarcoma population.
Themes
The first research question is answered by the first two themes, which are organized according
to our conceptual framework. The other two main themes, ‘reflection of diagnostic pathway’
and ‘recommendations for improvement of the diagnostic pathway’ give an answer to the sec-
ond aim of this study, to describe the impact of RtD length on QoL and care satisfaction of sar-
coma patients. The third research question is accounted for under all themes. Fig 2 shows a
schematic representation of our main findings, quotes to support our results can be found in
Table 2.
Theme 1: Patient interval: Appraisal and help-seeking
Appraisal. Three factors were identified that contributed to a long phase of appraisal.
First, many patients had an alternative, benign explanation for their symptoms. In some cases,
this alternative explanation was not something a patient would need to seek the help of a HCP
for (e.g. a bug bite), while in other cases the symptom was normalised by the patient as being
part of life (e.g. old age). Second, if the symptoms did not interfere with daily life, most patients
did not feel the urge to seek help. The process of help-seeking was often delayed further due to
other life priorities (e.g. a holiday), stopping with activities that became difficult due to symp-
toms (e.g. gardening), and treatment from a paramedical HCP which decreased complaints
temporarily. Third, many patients expected their complaint to cease by itself.
Help-seeking. The main trigger of help-seeking was interference of the symptoms with
daily life. If symptoms lasted or became worse, this was an extra reason to seek help. There
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Table 1. Patient and diagnostic interval characteristics.












































1 24 M High-grade
osteosarcoma of the
radius
26 3 23 6 2 / 1 13 2 / 1 4 2 / 1




49 16 33 1 2 / 1 27 9 / 6 5 1 / 1
3 40 F Solitary fibrous
tumour pelvis with
multiple metastases
32 0 32 23 2 / 2 7 6 / 4 2 3 / 2
4 65 F Leiomyosarcoma
uterus with liver
metastases
10 3 7 2 2 / 1 6 6 / 2 0 n.a.
5 41 F High grade
osteosarcoma
femur
22 11 11 0 1 / 1 1 2 / 1 10 3 / 1
6 54 F Solitary fibrous
tumour wrist
137 119 18 4 2 / 1 8 2 / 1 6 2 / 1
7 18 M Ewing sarcoma
cerebellum
15 12 3 1 2 / 1 0 1 / 1 2 2 / 1
8 69 F Solitary fibrous
tumour groin
13 0 13 5 2 / 1 9 2 / 2 0 n.a.




22 9 13 5 2 / 2 9 3 / 1 0 n.a.




99 57 42 6 2 / 1 36 5 / 1 0 n.a.
11 50 M Extra-osseous
Ewing sarcoma
thorax
64 4 59 0 1 / 1 56 5 / 3 3 2 / 1
12 48 F Extra -osseous
Ewing like sarcoma
thorax
145 4 140 137 6 / 2 0 2 / 1 3 3 / 2
13 61 M Retroperitoneal
dedifferentiated
liposarcoma
24 4 20 14 3 / 3 2 1 / 1 4 2 / 2




16 1 16 13 3 / 1 0‡ n.a. 3 2 / 2
15 69 M Well differentiated
retroperitoneal
liposarcoma
10 1 8 0 1 / 1 7 2 / 1 1 2 / 1
†Patients 1–7 were Dutch, patients 8–15 were English. ‡Direct referral from GP to sarcoma centre.
https://doi.org/10.1371/journal.pone.0243439.t001
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were no delays in making an appointment with an HCP. There were no remarkable differences
in the patient interval between NL or the UK.
Fig 2. Schematic representation of main findings.
https://doi.org/10.1371/journal.pone.0243439.g002
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Table 2. Quotes.
Theme Subtheme Quote
Patient interval Appraisal ‘Initially we thought it was a, like a bug bite’ (male, #11).
‘I stopped doing sport and waited without having any concerns’ (male, #1).
‘I was made this appointment at a back-specialist clinic and again he [a
physiotherapist] completely examined me and he quite 100% told me that you have got
a class-3 classic sciatica. He just said, keep taking your medication, you’re on the best
medication that you can get. [. . .] Well, with that I then continued’ (male, #13).
Help-seeking ‘I waited until it started to affect my style of life. I do a manual job [. . .]. So, I carried on
until basically it started to affect, you know, my daily work’ (male, #13).
‘Then last year around about Christmas time we noticed it getting much bigger and
taking on a red, a reddish, sort of like a bruise. So, and it started becoming quite can I
say noticeable. I couldn’t put my arm down properly and couldn’t sleep on that side.
And it did start giving me pain’ (male, #11).
‘At that moment the pain became worse, [. . .]it really hurt in the buttocks and the back
of my legs. I thought, this really can’t be any good’ (female, #4).
‘What made me decide to [make an appointment]? Because it wasn't getting better.
More frequent I expect and a lot of. . .soreness in the lower abdomen.’ (female, #9).
‘I was just getting scared because the pain, the pressure in the ribs, it wasn’t going away.
And I did have coughs and things like that, then they went away, then a lot of mucus
then they went away. But it just, you know, something wasn’t right’ (female, #12).
Diagnostic interval Diagnostic phase ‘” It’s a hematoma because you’ve obviously pulled a muscle and you know you’ve
pulled a muscle and it looks much like a hematoma” they said. [. . .] You don’t like to
dreadfulize, you don’t like to think what ifs. I had pulled muscles in the past and they
have been painful, and I have had problems with back muscles in the past through
dangerous sports, so I just assumed at the time that they were correct, it was a
hematoma.’ (female, #14)
‘Waiting for 6 weeks for an MRI is actually extremely long I think. If I would have been
aware that it might not be benign, I would not have agreed with that. But I wasn’t, so I
just went on a holiday, spent the entire day in the sun and drank alcohol. I was
extremely, extremely, extremely tired’ (male, #1).
‘The referral for that second opinion at the sarcoma centre had to go through the GP’
(male, #2).
‘The GP never referred me to get a CAT-scan because they [the GP] said I was fit,
healthy, non-smoker, never had any family condition or history of anything bad. I had
no pre-existing conditions of anything and I took no medication at all, so they said that
there was no reason for a CAT-scan. [. . .] So, they stopped there and every time I went
back they thought it was musculoskeletal’ (female, #12).
‘[. . .] and then a biopsy 3 times. They punctured 3 times, so they would have enough,
but they hadn’t because it turned out they were still in doubt between a
chondrosarcoma and an osteosarcoma. After that I got a biopsy under general
anaesthesia and that showed it was an osteosarcoma, but low grade. [. . .] Then I had an
operation, which went well, but they found other, more aggressive, cells, which is why I
had to come here [medical oncology department] eventually’ (male, #1).
‘They had to send the tissue sample to another hospital because they weren't sure, I
think that's when they pushed back the appointment and then when they had it
confirmed at the hospital they brought it [the appointment] forward’ (female, #10).
‘But it wasn’t the same doctor. The first time I saw, I had seen my own doctor but the
second time it was another doctor’ (male, #13)
‘So, my GP looked and investigated me but did not know what it was, so he sent me for
an ultrasound that same afternoon’ (female, #5).
‘The doctor said: “if I had not seen you on Sunday and I had not seen the difference
between Sunday and Friday, then I probably would not even have referred you to the
hospital”‘ (male, #7).
Effect of centralisation ‘Yes, I had to get used to the travel distance. [. . .] The travel costs, it was my savings I
used. You can ask something back from the insurance company, that is nice, but in the
beginning it did cost a bit more money’ (male, #1).
(Continued)
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Theme 2: Diagnostic interval: Diagnostic phase and effect of centralisation
Diagnostic phase. Once the patient seeks help from a HCP, he or she enters the diagnostic
phase. This phase was found to be lengthened by six factors, which could send patients back to
the process of appraisal.
First, the HCP often had a “working diagnosis” for which wait-and-see management was
legitimate. However, a lack of follow-up to ensure resolution of symptoms attributed to a long
diagnostic phase.
Second, the process of additional investigations was prolonged: (1) performing investiga-
tions was often postponed, (2) passive waiting time for imaging studies and biopsies, (3) long
time between investigations and receiving results, and (4) absence of subsequent investigations
if results were inconclusive or (false) negative.
Third, referrals took a long time due to: (1) referrals to the wrong specialist, (2) second




Reflection on diagnostic pathway Care satisfaction ‘[Getting the diagnosis took] roughly 4 months. If I look back at those dates, perhaps two
or three weeks might have been saved by a referral being sent on as soon as I was seen as
opposed to me phoning up to see if that had gone. So, apart from that I can't really, fault
anybody or the process of the system.’ (female, #8).
‘I’m very angry. I’m not saying that they. . . [pause], it could’ve been done better. [..] For
me to get where I am now I don’t think it would’ve [been necessary]’ (male, #13).
‘Well I suppose if I had been a private patient, I would have been seen and all this would
have happened maybe half the time or maybe less. So on looking at the NHS I'm being
realistic and thinking they have done the best they can.’ (female, #8).
‘But. . .it's a case, when they're all available. They are very, very pushed. I think there's
too many patients in our practice anyway.’ (female, #9).
Impact of receiving the
diagnosis
‘I entered the room and he said: “I have not got good news for you”. I then thought:
“wow”. It was like a rollercoaster. I had gone alone. I was startled, absolutely. No, I
really did not see it coming. It came out of nowhere.’ (male, #1).
‘Everybody said the chances of it being anything suspicious were absolutely minute, so I
had no reason to feel concerned at all. To be told. . .actually that's not what you thought
it was. Alright, okay where do we go now? [..] I was just so surprised after everything
being. . .”yes, yes everything looks good, everything looks good”. Then bang. . . [..] They
don't know how to express too much sympathy.’ (female, #10)
Impact of delay on medical
outcomes and quality of life
‘Yes, I understand it does influence my prognosis’ (male, #2).
‘It was difficult from the moment of the result at the hospital until the scans. Especially
after the scans I was wondering: “is it somewhere else, how bad is it?” I thought I was
dying.’ (male, #1).
‘I suppose the most difficult part was not knowing, or waiting, knowing that in all these
investigations would obviously help towards the diagnosis and just waiting and not
knowing. [..] But never the less I just got on with life.’ (female, #8).
Advice Recommendations for
improvement of the diagnostic pathway
‘Be persistent for what you want [to know]. If you don't know [what’s going on] and you
want to know then you just have to be persistent about it’ (female, #9).
‘Everything could have gone faster if people had been more aware that this could be
sarcoma’ (male, #1).
‘A patient should at the moment of getting complaints of peeing or whatever take it
seriously straight away’ (female, #3).
‘The key is to start with your general practitioner’ (female, #5).
‘Possibly my doctor himself should have pushed slightly more rather than saying: yes,
that’s fine, you can leave it until after your holidays, [the GP] should’ve possibly said:
“no, let’s fix it beforehand”‘ (female, #14).
https://doi.org/10.1371/journal.pone.0243439.t002
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Fourth, if the course of disease progression was different than expected, often the working
diagnosis was not adjusted, and no new investigations were ordered.
Fifth, if a biopsy was performed it took a long time to get a diagnosis due to the rarity of the
disease, heterogeneity and difficulty to diagnose, more tissue needed or necessity to send the
material to a sarcoma pathologist.
Sixth, the lack of a lead clinician lengthened the diagnostic process, e.g. when a patient was
repeatedly referred to a different specialist at another hospital, or if follow-up consultations
did not take place with the same doctor. This was more evident in English than in Dutch inter-
views, whereas the other causes were mentioned by both groups of patients.
Similarly, the reverse of these factors led to a short diagnostic interval. Especially investiga-
tions done within a short time frame, smooth referrals, awareness of the patient that something
was wrong and having one lead clinician facilitated fast diagnosis.
Effect of centralisation. Many patients acknowledged centralisation of sarcoma care had
been difficult in terms of travel distance, arranging transport, the necessity to take longer time
off from work, and paying travel expenses from their own savings, especially in the UK.
Although travelling to a sarcoma centre or being admitted away from home felt as an effort, it
was not a barrier for them to visit a sarcoma centre as they believed they received better care.
Theme 3: Reflection on diagnostic pathway: Satisfaction with care and
impact of delay
Care satisfaction. Patients were satisfied about the received care if (1) HCPs kept their
promises, (2) information provision was satisfactory, and (3)patients felt they were taken seri-
ously. The absolute length of the diagnostic interval was mostly not of influence on the level of
satisfaction with care, but the (subjectively) experienced length was important.
Patients were unsatisfied if (1) there were long waiting times, (2) they felt their symptoms
were ignored, (3) they were falsely reassured, and (4) information provision was inadequate.
In the UK patients felt that their doctors were busy, and the system was pushed, therefore not
faulting their doctor but the system they needed to work in. They thought this caused GP’s to
be less proactive and thought waiting times were longer due to the National Health Service
(NHS) and would have been shorter if they were privately insured. This was not applicable to
Dutch patients.
Impact of receiving the diagnosis. Most patients who experienced a long diagnostic
interval felt shocked when they received the diagnosis. Those who experienced a short diag-
nostic interval were more concerned about their loved ones than themselves.
Impact of delay on medical outcomes and quality of life. Only one patient thought a
long diagnostic interval influenced his clinical outcomes. However, the emotional burden with
feelings of anxiety, fear of dying, and anger was mentioned by most patients. The impact of a
long interval on quality of life was largest when patients had not expected a malignant diagno-
sis. They also experienced the period in which they knew they had a malignancy but had to
wait for the definite diagnosis as difficult.
Theme 4: Recommendations for improvement of the diagnostic pathway
Patients gave advice regarding improvements of the diagnostic pathway. First, awareness of
both the patient and HCP was described as a requisite for an efficient diagnostic pathway.
Awareness leads to investigations being done in a shorter time frame due to persistence of
patients or recognized necessity for investigations by the HCP. Second, patients indicated they
can be empowered by receiving copies of referral letters. Third, each patient should have a lead
clinician, who tracks results of investigations until a diagnosis has been made. Many patients
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emphasized the importance of the role of the gatekeeper, most often the GP. If the gatekeeper
ordered the right investigations or referred them to the correct specialist most RtD’s went
smoothly. If the gatekeeper reassured them, referred to the wrong specialist, or postponed
investigations or referrals, then patients lingered for a long time. These recommendations
were the same among Dutch and English patients.
Discussion
This study investigated the RtD as experienced by sarcoma patients, its effect on QoL and care
satisfaction and differences between English and Dutch patients. We found the RtD to be vari-
able and many sarcoma patients encounter difficulties during the process. The total interval of
our patients varied from 10 to 145 weeks, this large variability is concurrent with the literature
[13].
Our study identified four main themes: patient interval, diagnostic interval, reflection on
diagnostic pathway and recommendations for improvement of the diagnostic pathway; Fig 2
shows a schematic summary of our main findings.
Factors influencing the length of the patient interval were alternative explanations for
symptoms, interference with daily life, expectations about prolongation of symptoms and wait-
ing time for appointments. The diagnostic interval was lengthened if the working diagnosis
was inaccurate or not adjusted, the process of investigations and receiving their results was
inefficient, there was a lack of a head clinician, or there were long referral times. These associa-
tions are in concurrence with existent cancer literature, which has shown that key concepts for
length of patient and diagnostic interval were recognition and interpretation of symptoms, the
impact on everyday life by symptoms, experiences of generalist health care, entry into second-
ary care, repeated cycles of healthcare seeking and appraisal without resolution and lack of fol-
low-up of persisting symptoms [15–17, 19, 20]. As shown in our study, the role of the GP or
subsequent lead clinician is important for referral times and promptness of successive addi-
tional investigations.
Sarcoma care is centralized in sarcoma expert centres in many countries, it is generally
accepted that this improves diagnosis and subsequent treatment [1, 2]. We explored the effect
of centralisation on patients’ experiences of the diagnostic pathway. For nearly all included
patients, travelling to a sarcoma centre was time consuming and costly, but not withstanding
them from going there to receive the best possible care.
Although the diagnostic interval was perceived more negative by English patients, care sat-
isfaction was equal amongst Dutch and English participants. An interesting finding is that the
absolute duration of the diagnostic interval was not of influence on care satisfaction as
reported by our participants. They were unsatisfied with passive waiting time, being ignored
or falsely reassured, and if information provision was inadequate. The reverse of these factors
improved their level of care satisfaction. To the best of our knowledge, the influence of RtD on
care satisfaction has not been measured. However, there is a lot of literature and policy reports
measuring RtD length including anecdotal evidence that the large number of prolonged time
to diagnosis will lead to lower care satisfaction [11, 21, 22]. The European patient advocacy
group (SPAEN) has written a position paper in which the first priority challenge is earlier
accurate diagnosis [23]. This underlines the importance of a fast RtD for patients. Delays to
diagnosis have also been shown to be the main cause of sarcoma litigation [24, 25]. General
cancer literature has shown contradictory results about the relation between care satisfaction
and experienced RtD; a qualitative study with 26 patients with anal cancer showed most
patients were satisfied with received care, unless they experienced passive waiting time [26].
However, another study in 353 women with gynaecological cancer reported a longer
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diagnostic interval led to lower care satisfaction [7], and a study in 904 cancer patients showed
patients had less confidence in GPs after being diagnosed with a doctor delay [27]. Upon
receiving the diagnosis patients with a long interval felt shocked, those with a shorter interval
were mainly worried about their family.
Research about the effect of the length of total on clinical and patient-reported outcomes is
mostly retrospective and shows contradictory results [11]. However, a long total interval could
cause significant psychological morbidity [6]. Participants in our study confirm that waiting
time causes psychological distress. Yet, only one patient considered his delayed diagnosis to
influence his clinical outcome. This is an additional rationale to investigate the effect of the
length of diagnostic interval on both clinical as well as patient-reported outcomes.
The fourth theme, recommendation for improvement of the diagnostic pathway, provided
us with information consistent with existing cancer literature but now from a patients’ per-
spective: the main recommendations were to increase awareness amongst patients and HCPs,
to empower patients, and to have one lead clinician [10, 15, 20].
This study has given us insight in the patients’ perspective of the diagnostic pathway. Never-
theless, several limitations should be considered. First, although qualitative study methods are
ideal to gain insight in what is important and why, this is a descriptive study and results can
therefore not be generalized to all sarcoma patients. The RtD is influenced by healthcare sys-
tems, culture and organization of care and therefore these results cannot be generalized to sar-
coma patients outside NL or the UK. In our analyses, the same factors facilitating and
prolonging time to diagnosis emerged from all interviews. In that respect, we concluded we
reached data saturation and did not add any more participants. However, due to the heteroge-
neity of the disease, depending on subtype and location, patients will encounter many different
specialist in the RtD. As shown in this study, this results in many different pathways and we
cannot say we explored all possible cases. Second, one of the aims of our study was to examine
the effect of the RtD on QoL. However, the impact on QoL was not a main issue in our inter-
views. To investigate whether QoL is truly not impacted by length of the total interval, quanti-
tative research is needed. Third, we left the treatment interval out of the scope of our study.
Outcomes may be influenced by this time interval, and some patients had just heard their diag-
nosis whereas others had already started treatment, which may have influenced their
responses. Fourth, patient interval dates were patient-reported and therefore possibly inaccu-
rate. To limit recall bias, we included and interviewed patients within four months after diag-
nosis, in our clinical experience patients remember many details about their RtD, we therefore
think this bias is limited.
Until now, the conceptual framework used to describe the RtD was a theoretical model rep-
resenting methodological recommendations. Our study described the patient experience of
sarcoma diagnosis and for the first time confirms that this patient experience fits the model.
This is an important finding, because understanding the RtD from both the patient and clini-
cal perspective is necessary to improve the diagnostic pathway.
Our study confirms the research model as presented in Fig 1 is useful for sarcoma patients
and can be used in future research to report uniformly on the subject. The fig could be given
more detail specifically for sarcoma patients, e.g. contributing events could be complemented
with patient awareness and empowerment for patient factors, direct access to investigations
and having a lead clinician are important system factors and care satisfaction is influenced by
passive waiting times. However, to make these findings more robust and to study the effect of
total interval on outcomes, more research is needed. This qualitative study was used to identify
factors important to patients, to use in our design of a large quantitative and prospective longi-
tudinal study, currently a trial in progress (the ‘QUEST’ study, NCT03441906). This study will
allow us to quantify total interval and its components, provide insight in factors contributing
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to its length, and study the relationship between its length and clinical as well as patient-
reported outcomes. If the sample is large enough, we may be able to distinguish these features
for specific sarcoma subtypes. Hopefully it will allow us to give a more detailed insight in what
is specific in the RtD for sarcoma patients, compared to other malignancies. The present study
has contributed to understanding patients’ experiences during the diagnostic process and has
enabled us to design a study in which the patients’ perspectives are involved.
Conclusion
This study confirmed RtD for sarcoma patients is variable and found several patient and sys-
tem factors influencing its length for English and Dutch patients, and described its effect on
care satisfaction. The total interval could be reduced by increasing awareness amongst patients
and HCPs, having an efficient pathway for investigations and referrals and working with a lead
clinician. Centralisation of care is costly and time consuming, but not a barrier for receiving
care. The patients’ experience of the RtD could be improved by reducing passive waiting time
and providing adequate information. Quantitative research is needed to confirm these findings
and study the impact of RtD on clinical and patient-reported outcomes.
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